Targeted Therapy With Lapatinib in Patients With Recurrent Pituitary Tumors Resistant to Standard Therapy

NCT00939523 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

9

Enrollment

OTHER

Sponsor class

Conditions

Pituitary Adenomas
Prolactinomas

Interventions

DRUG: Lapatinib

Sponsor

Cedars-Sinai Medical Center